Day 1 in Lund highlighted a clear direction: global policy shifts are increasingly shaping local HTA realities.
External changes, including US MFN policy, are already influencing the pharmaceutical landscape beyond their origin.
Less than a year on, the impact feels well embedded.
At the same time, innovation is shifting toward more specialised therapies.
This is adding pressure to value-based pricing frameworks and challenging established standards.
As highlighted by keynote speaker Amanda Cole, innovative payment models may become part of the solution.
Key discussions today included:
📌 whether current willingness-to-pay thresholds remain fit for purpose
📌 the limited scientific basis behind commonly referenced “unofficial” thresholds
📌 how systems can adapt to increasing complexity
A lively exchange between Linköping University and IHE/Lund reflected both differing perspectives and shared uncertainty.
💡 The common thread: complexity in HTA decision-making is increasing, not easing.
Konstantin Macheridis and Hannah Norman are on site tomorrow, for Day 2.
Please feel free to reach out if you would like to continue the conversation.
What changes are you observing in pricing and HTA discussions across your markets?
